Corbus Pharmaceuticals (NASDAQ:CRBP) Given Buy Rating at HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) in a research report report published on Monday,Benzinga reports. The firm currently has a $75.00 target price on the biopharmaceutical company’s stock, down from their previous target price of $80.00. A number of other equities research analysts also recently commented […]
HC Wainwright reaffirmed their buy rating on shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) in a research report report published on Monday,Benzinga reports. The firm currently has a $75.00 target price on the biopharmaceutical company’s stock, down from their previous target price of $80.00. A number of other equities research analysts also recently commented […]
